Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 12/20 | 0.64 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661951 | 0.93 | F2R (0.70) | F2RUSP30NPC1RAB9A | |
| SCHEMBL661343 | 0.85 | F2R (0.70) | F2RCYP2C19 | |
| SCHEMBL486316 | 0.84 | F2R (0.60) | F2RRAB9ACYP2C19 | |
| SCHEMBL10242070 | 0.84 | F2R (0.86) | F2RCYP2C19 | |
| Hydrochloric Acid SCHEMBL485864 | 0.83 | F2R (0.84) | F2RCYP2C19 | |
| SCHEMBL17135692 | 0.81 | F2R (0.62) | F2R | |
| SCHEMBL10242029 | 0.81 | F2R (0.62) | F2RUSP30 | |
| SCHEMBL661509 | 0.80 | F2R (0.79) | F2RNPC1RAB9A | |
| SCHEMBL485923 | 0.79 | F2R (0.73) | F2RCYP2C19 | |
| SCHEMBL10241116 | 0.78 | F2R (1.00) | F2RNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411363-B1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2411363-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | Bayer Pharma AG (DE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | F2R, F2RL1, F2RL3 | F2R 1/4885USP30 2434/4885NPC1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.